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Abstract 
Neurofibromatosis type 1 (NF1) is an autosomal dominant tumour predisposition syndrome that is 
caused through loss of function mutations of a tumour suppressor gene called Neurofibromin 1. 
Therapeutic options are currently limited for NF1-associated tumours, where treatment is often 
restricted to complete surgical resection with clear margins. Herein, we discuss the multifunctional 
tumour suppressive role of neurofibromin, which is classically known as a GTPase activating protein 
(GAP) towards the RAS small GTPase. While neurofibromin inhibits proliferative growth through 
blockade of RAS-mediated signal transduction, neurofibromin should also be considered as a 
modulator of cell motility and cell adhesion. Through interfacing with the cytoskeleton and 
membrane structures, neurofibromin acts as a negative regulator of RHO/ROCK signalling pathways 
involved in cytoskeletal dynamics that are instrumental in proper neuronal development. In the 
context of cancer when the normal function of neurofibromin is lost via genetic mutation, 
heightened proliferative drive and an innate ability to migrate are key attributes that predispose NF1 
patients to cancer. Malignant Peripheral Nerve Sheath Tumours (MPNST) can develop from benign 
neurofibromas and are the main cause of death amongst NF1 patients. Through recent research on 
MPNSTs, we have much more insight into the key molecular events that drive their malignancy. 
Advances regarding malignant drivers involved in cell migration, cell invasion and angiogenic 
signalling are discussed in this review, where these findings will likely influence future therapies for 
both NF1 and related sporadic cancers. 
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1. Introduction  
NF1 (MIM 162200) is an autosomal dominant tumour predisposition syndrome with an incidence 
of 1 in every 3500 births. The description of individuals with NF1 has been well-documented 
throughout history, going as far back as the thirteenth century. NF1 became synonymous with von 
‘eĐkliŶghauseŶ͛s disease afteƌ FƌiedƌiĐh DaŶiel VoŶ ‘eĐkliŶghauseŶ gaǀe a ĐlassiĐ desĐƌiptioŶ of 
Neurofibromatosis in 1882 [1]. NF1 is recognised for the variety of tissues and organs it can affect 
and also for its variation in disease expression within individuals. Even amongst family members, the 
manifestations of NF1 can vary quite markedly.  
NF1 is often diagnosed early on in childhood through the presence of café-au-lait spots (observed 
in 99% of NF1 patients), which are dark pigmented patches on the skin, as well as inguinal/axillary 
freckling [2]. Other clinical features observed during childhood are benign growths called Lisch 
nodules that often form within the iris but do not usually impair vison. However, some affected 
patients can also develop optic gliomas, tumours that grow along the optic nerve to the brain, 
leading to reduced vison or even blindness. Other symptoms commonly associated with NF1 include 
hypertension, short stature, and macrocephaly. Skeletal abnormalities are also apparent, such as 
abnormal curvature of the spine (scoliosis). Later in adulthood, NF1 patients frequently develop 
neurofibromas that are benign nerve sheath tumours that are located on or just beneath the skin 
and can also commonly arise from nerves near the spinal cord and brain. Neurofibromas comprise of 
a mixture of Schwann cells (peripheral nerve support cells), perineurial-like cells and fibroblasts. 
There are two main types of neurofibromas called dermal neurofibroma and plexiform 
neurofibromas. Dermal neurofibroma can present either on the skin (cutaneous), beneath the skin 
(subcutaneous), or deep underneath the dermis (nodular). Plexiform neurofibromas can arises from 
major nerve branches from the skin [2], where these are typically congenital (effecting 60% of NF1 
patients) and develop within peripheral nerves and their perineural sheaths. Plexiform 
neurofibromas are characteristically hyper-proliferative, leading to enlarged tumours that can affect 
entire body sections and can encroach on vital organs and structures. Consequently, plexiform 
neurofibromas can be debilitating, causing significant discomfort, disfigurement, neurological 
deficits and is the major cause of morbidity in NF1 patients. Surgical removal of these tumours has 
proven to be more difficult than other types of neurofibromas due to its infiltrative nature [3]. 10% 
of plexiform neurofibromas can undergo transformation to highly invasive peripheral nerve 
sarcomas called malignant peripheral nerve sheath tumours (MPNSTs) that grow along nerves and 
typically metastasise to the brain and bone as well as other locations. 
It took over a decade to identify the causative gene of NF1, which posed a major challenge. In 
1987, gene linkage studies initially localised the NF1 gene to the pericentromeric region of 
chromosome 17. Later on, advanced mapping located the gene in a region close to the 17q11.2 [4–
6], which was then further refined within 3cM of 17q11.2 [4,5,7]. Cytogenetic studies of two 
unrelated NF1 patients with balanced translocation provided a more definitive position of the NF1 
gene, where the common breakpoints in both individuals was localised to the 17q11.2 region [8–10]. 
Finally, the NF1 gene was identified by positional cloning experiments at 17q11.2 in 1990 [11,12]. 
The NF1 gene has a high mutation rate, approximately one mutation occurring per 10,000 
gametes per generation (100 times greater than many other genes). The high mutation rate in the 
NF1 gene could possibly be due to its large size (350 kb with 60 exons). Within individuals affected, 
approximately 255 mutations have been observed, leading to protein truncation and abnormalities. 
As with most tumour suppressors, heterozygous loss of function mutations of NF1 is responsible for 
disease. NF1 patients have a higher cancer incidence compared to the general population, with 
increased risk of gastrointestinal tract, liver, lung, bone, thyroid, breast and ovarian cancer [13]. As 
well as predisposing NF1 patients to cancer, mutation of the NF1 gene is often sporadically mutated, 
where mutation frequency of NF1 occurs in 5-10% of non-NF1 associated sporadic cancers such as 
glioblastoma, neuroblastoma, acute myeloid leukaemia, breast cancer, lung cancer and ovarian 
cancer. 
2. NF1 tumour suppressor and oncogenic Ras in cancer 
The NF1 gene encodes a tumour suppressor protein known as neurofibromin that is a large multi-
domain protein (~250 KDa, containing 2,818 amino acids) [14]. Neurofibromin plays an upstream 
repressive role in the regulation of RAS small G-proteins. RAS switches between two conformation 
states and is active when GTP-bound or inactive when GDP-bound. This GTP/GDP switching is 
controlled by two opposing activities, which are governed by either GTPase activating proteins 
(GAPS) or guanine nucleotide exchange factors (GEFs). The GAP related domain (GRD) is central to 
the tumour suppressive role of neurofibromin that functions as a GAP towards RAS small G-proteins. 
Through this GRD, neurofibromin binds to and enhances the intrinsic GTPase activity of GTP-bound 
RAS, which switches RAS to an inactive GDP-bound state. Consequently, inactivating disease causing 
mutations of neurofibromin leads to constitutive GTP-loading and hyperactivation of RAS. There 
exists a large and diverse family of functional RAS GAPs, which includes not only neurofibromin, but 
also p120GAP, GAP1IP4BP, Ca
2+
-promoted RAS inactivator, RAS GTPase activating-like protein 
RASAL, DAB2IP, nGAP, and SynGAP. In neuronal cell linages, i.e., neural crest-derived tumours such 
as neurofibromas, neurofibromin is thought to function as the predominant GAP towards RAS, which 
might help explain why NF1 patients are predisposed to these tumour types. SOS, RasGRF and 
RasGRP all directly oppose the action of Neurofibromin by functioning as the RAS GEF to exchange 
bound guanine nucleotide to GTP [15,16]. When actively GTP-bound, RAS associates with effector 
enzymes and results in activation of signalling pathways that control cell survival and proliferation 
[17]. Upon loss of neurofibromin function and RAS activation, a higher level of proliferative drive 
likely accounts for the large irregular tumour mass of plexiform neurofibromas as well as their 
cancer progression to MPNSTs. Cell proliferation would likely act as a mutation accelerant that 
would progress the benign plexiform neurofibromas towards malignancy. 
Due to hyperactivation of RAS, NF1 is classed as a RASopathy. There are three closely related RAS 
small G-protein family members, HRAS, KRAS and NRAS (85% amino acid identity) [17,18]. Upon loss 
of NF1, transformation is driven mostly through hyper-activation of KRAS. In the context of sporadic 
cancers, activating mutations within KRAS is a more common early event in cancer progression 
(21.6%), when compared to activation mutations of either NRAS (8%) or HRAS (3.3%). One of the 
main downstream effectors of RAS is the protein serine/threonine kinase RAF. Studies have shown 
that active GTP-bound RAS binds to and activates all three related RAF proteins (c-RAF1, BRAF and 
ARAF). Interaction between RAS and RAF results in re-localisation of RAF to the plasma membrane 
where it is then activated to drive the Mitogen-activated protein kinase (MAPK) signalling cascade. 
RAF does this through phosphorylation and activation of mitogen-activated protein kinase (MEK) 
that then subsequently phosphorylates and activates extracellular signal-regulated kinases 1 and 2 
(ERK1/2) downstream in the MAPK signalling pathway (see Figure 1). Active ERK1/2 then 
translocates to the nucleus, where they orchestrate a transcriptional programme that drives cell 
proliferation [19,20]. 
3. Domains of neurofibromin linked to tumour formation and neuronal function 
While the GRD has been researched extensively and is considered the principle domain that 
suppresses tumour formation by reverting RAS to an inactive GDP-bound state, the other less well-
characterised domains are of equal importance for the function of neurofibromin. Key functional 
domains of neurofibromin also include the Sec14 and pleckstrin homology (PH) domain (referred to 
as the ͚SeĐϭϰ-PH ŵodule͛Ϳ as well as the C-terminal domain (CTD). The presence of multi-functional 
domains within neurofibromin suggests that it acts as a large scaffold to interface with multiple 
proteins to coordinate signalling events central to neuronal function and development (refer to 
Figure 1 for functional domains known to be involved in tumour suppression).  
3.1 Sec14-PH module of neurofibromin is essential for tumour suppression and regulates the 
cytoskeletal through LIMK 
In the central region of neurofibromin (proximal to the GRD) the Sec14-PH module resides, which 
facilitates binding of neurofibromin to membrane surfaces and vesicular trafficking within the 
endomembrane system. While the PH domain tethers neurofibromin to membranes surfaces 
through binding to phosphatidylinositol lipids on membranes, the Sec14 domain allows for active 
trafficking of neurofibromin between membrane structures. Spatial localisation of neurofibromin to 
lipid platforms on membrane surfaces within the cell is thought to proximally deactivate RAS that is 
also membrane tethered. Membrane anchoring of RAS is mediated via a prenylation moiety that is 
added post-translationally to the extreme C-terminal CAAX motif of RAS ;ǁheƌe ͚A͛ refers to an 
aliphatic residue). The Ras-GAP activity of neurofibromin within cells absolutely requires this Sec14-
PH module [19,20], which implies that the correct spatial localisation of neurofibromin to membrane 
structures is needed for it to function as a RAS GAP. Furthermore, membrane tethering of RAS via 
prenylation is necessary for its transforming capacity [21-23], implying that RAS needs to be localised 
appropriately to membranes to relay downstream signalling. Initial investment went into drug 
therapies to inhibit RAS prenylation with the notion that this would block oncogenic RAS signalling. 
While farnesyltransferase inhibitors (FTIs) showed promise as an anti-cancer agent, it was later 
apparent that RAS prenylation was not exclusively post-translationally modified by 
farnesyltransferases, but could also be modified by geranylgeranyltransferases. This redundancy 
regarding RAS prenylation reduced enthusiasm to progress further with FTI therapies as a means to 
inhibit RAS. The observed anti-tumour activity of FTIs is likely through inhibition of other prenylated 
GTPases. One good GTPase candidate is Rheb (RAS homology enriched in brain), which unlike RAS is 
exclusively prenylated through farnesyltransferases. FTIs can sufficiently block Rheb signalling 
towards mechanistic target of rapamycin complex 1 (mTORC1) [24], known to drive cell growth and 
angiogenesis [25]. 
Of interest, Ozawa et al. showed that interfering knockdown of neurofibromin led to excessive 
actin stress fibre formation that was due to activation of the RHO signalling pathway involving LIM 
domain kinase 2 (LIMK2) [26]. LIMK2 (as well as LIMK1) are substrates of RHO-associated, coiled-coil-
forming protein kinase (ROCK), which is the downstream effector of RHO. While the mechanism of 
action was first perceived to be through hyperactive RAS signalling, a more recent study implicated a 
direct interaction with neurofibromin and LIMK2. LIMK2 was found to interact with the Sec14-PH 
module in a yeast two-hybrid screen using the Sec14-PH module as bait. Cytoskeletal reorganisation 
is important for many cell processes, such as cell motility, cell adhesion, cytokinesis, and is 
particularly important for neurite extension. LIMK2 is a dual Serine/Threonine and Tyrosine protein 
kinase involved in cell cycle control, cell migration and also neuronal development. In the disease 
setting of NF1, LIMK2 activity is elevated, leading to actin cytoskeletal reorganisation. LIMK2 does 
this thƌough phosphoƌylatioŶ of ĐofiliŶ, ǁhiĐh iŶhiďits ĐofiliŶ͛s aĐtiǀity to disassemble actin via 
depolymerisation and as a consequence lengthens actin structures. Furthermore, neurofibromin was 
recently shown to act as a negative regulator of the RAC1/PAK1/LIMK1/cofilin pathway 
independently of RAS signalling [26].  
3.2 The C-terminal domain of neurofibromin acts as a protein scaffold that regulates neuronal 
development and growth 
As well as being involved in actin rearrangements, neurofibromin interacts with the microtubular 
and microfilamentous cytoskeleton [27]. Through the C-terminal domain neurofibromin was initially 
shown to interact with Focal Adhesion Kinase 1 (FAK1, also known as protein tyrosine kinase 2) and 
were observed to co-localise within mammalian cells [28]. A more recent study using genetics and 
protein interactions within Drosophila models of NF1 revealed that neurofibromin is a downstream 
target of FAK1 (known as Fak56  in Drosophila), where FAK1 interacted with the N-terminal region of 
NF1 in a Ca
2+
-dependent manner [29]. In this study, Tsai et al. showed that synaptic transmission 
was increased upon loss of NF1, indicating that NF1 is important for normal synaptic function. FAK1 
is involved in cerebral cortex lamination, axon branching and pathfinding, and synapse formation. 
These studies show that FAK1 can bind to both the N-terminus and C-terminus of neurofibromin. 
As FAK1 is a tyrosine kinase, it is tantalising to speculate that neurofibromin might be directly 
phosphorylated on specific tyrosine residues by FAK1 that could regulate its tumour suppressor 
function. Phosphorylation of neurofibromin by upstream kinases and delineation of signalling 
components downstream of neurofibromin has been poorly studied to date, and is currently a 
knowledge gap. Some advances have been made however. It is known that neurofibromin is 
constitutively phosphorylated within a cysteine/serine-rich domain (CSRD) as well as within the C-
terminal domain. Within the C-terminal domain, a cluster of cAMP-dependent protein kinase (PKA) 
phosphorylation sites have been identified (Ser2576, 2578, 2580, 2813 and Thr2556), where 
phosphorylation leads to 14-3-3 association that impedes neurofibromin͛s aďility to fuŶĐtioŶ as a 
RAS-GAP [30]. It is not currently known whether 14-3-3 binding to neurofibromin would impede 
translocation or protein-protein interactions of neurofibromin and downstream functions. 
Collapsin response mediator protein-2 (CRMP-2) is another interactor of neurofibromin that 
binds to the C-terminal domain [31]. CRMP-2 is involved cytoskeleton remodelling required for 
neuronal polarity via proper axon formation and growth cone guidance. Neurofibromin was seen to 
co-localise with CRMP-2 at distal tips and branches of extended neurites. Neurofibromin functions as 
a repressor of CRMP-2, as binding of neurofibromin to CRMP-2 represses the ability of upstream 
kinases (such as CDK5, GSK-3β, and ROCK1) to phosphorylate and regulate CRMP-2 [31]. 
4. MPNST, a model of malignancy 
It is clear that neurofibromin is critically involved in neuronal development and function through 
a multitude of functional domains that regulates cell motility and adhesion. It is therefore 
unsurprising that plexiform neurofibromas are at risk of becoming malignant. Therapeutic options 
are currently limited for NF1-related MPNSTs, which is the major cause of morbidity in NF1 patients. 
MPNSTs are high grade sarcomas that typically arise from pre-existing plexiform neurofibromas and 
are highly invasive. MPNSTs are relatively resistant to chemo and radiation therapy and such 
treatments can induce secondary malignant neoplasms [32]. As overall survival is poor with 
chemotherapy with a 5-year survival of 14 % [33], the main treatment for MPNSTs is complete 
surgical removal with clear margins [34]. Surgery is typically combined with adjuvant radiation 
therapy that reduces rates of local disease recurrence, but however, does not appear to lessen rates 
of distant metastases or overall survival [35]. After radical surgical resection, only 30% of patients 
will remain disease free after 5 years. MPNSTs have high levels of chromosomal alteration through 
genetic mutation and epigenetic modification, which results in their metastatic disease progression. 
Consequently, it has been a real clinical challenge to treat MPNSTs with targeted mono- and 
combination-drug therapies, which is due in part to these MPNSTs having a high level of intra-
tumoural molecular heterogeneity. 
While neurofibromas are characteristically benign, additional genetic events are essential for 
progression to MPNSTs and appear to derive from atypical neurofibromas [36]. Atypical 
neurofibromas are hypercellular PNSTs that have hyperchromatic nuclei with no sign of mitosis. We 
can learn a lot from MPNSTs, where they could be considered as a model of malignancy.  Genetic 
alteration, driven through loss of NF1 function and hyperproliferation and consequential genetic 
instability, leads to key signature events that are commonly found in other malignancies. It is likely 
that transformation of neurofibromas to MPNSTs involve key genomic alternations that alter the 
cells within neurofibromas to malignancy [36]. There are several genomic abnormalities within 
MPNSTs that are absent in the neurofibromas. 
4.1 Amplification of receptor tyrosine kinases in MPNSTs 
‘eǀealiŶg those ͚usual suspeĐts͛ of ĐaŶĐeƌ, loss of heterozygosity (LOH) analysis linked Tumour 
Protein P53 (TP53), Retinoblastoma protein 1 (RB1) and Phosphatase and tensin homolog (PTEN) as 
key gene markers of MPNST tumour progression; where these tumour suppressor genes are 
commonly inactivated in sporadic cancer. Through detailed analysis of malignant progression of 
benign neurofibromas to MPNSTs, several key advances have been made. Most notably, high-
throughput whole genome analysis with microarrays has been instrumental in determining the 
molecular pathophysiology of MPNSTs that revealed oncogenic signatures within MPNSTs, which are 
not present in benign neurofibromas [37]. MPNSTs are characteristically hyperdiploid and their 
genomes are highly rearranged. When looking at copy number variations, multiple receptor tyrosine 
kinases (RTKs) were implicated within the malignant tumours. For instance, gene amplification of the 
MET, EGFR, PDGFRA, IL-R genes frequently occur in MPNSTs [37-41]. Such insight into malignant 
progression led to both mono- and combination-RTK targeted strategies through the use of tyrosine 
kinase inhibitors (TKI), which initially appeared to be an ideal targeted therapy for NF1 patients with 
MPNSTs. 
While these initial therapies looked promising in pre-clinical studies [42], the use of mono-TKIs 
appeared to be less effective in NF1 patients. An open-labelled phase II study with Imatinib (also 
known as Gleevec®, a TKI against PDGFR) to treat MPNST patients  was terminated due to no effect 
(ClinicalTrials.gov identifier: NCT00427583). In vitro cell growth and proliferation as well as MPNST 
growth in the xenograft models revealed that three of the six MPNST cell lines tested were highly 
resistant to Imatinib treatment [43]. Drug resistance (both innate as well as acquired) is a major 
issue when using TKIs. Drug resistance likely develops through compensatory signalling pathways at 
the level of RTKs, where the network of RTK allows for a high level of flexibility and redundancy that 
hampers targeted therapies towards RTKs. There was initial enthusiasm, when a single MPNST 
patient with a high RAS signalling profile showed significant clinical response to lung metastases 
after treatment with a multi-TKI inhibitor, Sorafenib [44] (also called Nexavar®) that inhibits Vascular 
Endothelial Growth Factor receptor (VEGFR), PDGFR and Raf kinases. While Sorafenib looked 
promising in pre-clinical studies [45], Similar to Imatinib, there was a lack of efficacy in NF1 patients 
with MPNSTs in larger phase II trials as a mono-therapy (ClinicalTrials.gov Identifier: NCT00245102), 
and also when combined with chemotherapy (ClinicalTrials.gov Identifier: NCT00837148). 
4.2 Amplification of RHO signalling during malignant progression 
While we previously described neuƌofiďƌoŵiŶ͛s iŶǀolǀeŵeŶt iŶ ƌeoƌgaŶisiŶg the ĐytoskeletoŶ 
through LIMK and FAK1, the cytoskeleton is further dysregulated during NF1 disease progression. In 
a recent study, RAC1-dependent signalling was observed to be further amplified during progression 
of benign plexiform neurofibromas to MPNSTs [46]. Upadhyaya et al. performed single-nucleotide 
polymorphism genotyping and copy number alteration; LOH, and copy number neutral-LOH analyses 
of DNA isolated from 15 MPNSTs and directly compared them to both benign peripheral 
neurofibromas and patient-matched lymphocyte DNAs. Pathway analysis showed that MPNST 
specifically amplified RHO-GTPase pathway genes (RAC1 and ROCK2) as well as cytoskeletal 
remodelling/cell adhesion genes (FAK1 and LIMK1) [37]. Interfering RNA knockdown of RAC1, 
ROCK2, FAK1, and LIMK1 in MPNST-derived cell lines markedly enhanced cell adhesion, while wound 
healing, cell migration, and invasiveness were significantly reduced [37]. Such data reveals that these 
RHO-regulated genes are upregulated during malignant development of benign plexiform 
neurofibromas and are critical drivers of malignancy. 
4.3 Angiogenic signalling of MPNSTs and the involvement of STAT3 
Both the infiltrative nature of MPNSTs and the success with anti-angiogenic therapies, such as 
Sorafenib, in pre-clinical trials is highly suggestive that MPNSTs require angiogenic signalling for their 
malignant development. While assessment of vascularity in the late 1980s by transmission electron 
microscopy did not initially implicate angiogenic signalling in MPNSTs [47], a much more recent 
study postulated that MPNSTs likely ƌeƋuiƌe aŶ ͚aŶgiogeŶiĐ sǁitĐh͛ for their cancer progression [48]. 
Indeed, Gesundheit et al., uncovered that MPNSTs from five NF1 patients all displayed a structure of 
immature microvascular blood vessels that was ƌeŵiŶisĐeŶt to ͚spƌoutiŶg aŶgiogeŶesis͛. Importantly, 
these vascular observations were not present within the benign peripheral neurofibromas. Through 
recent research on angiogenic signalling, our lab discovered that signal transducer and activator of 
transcription 3 (STAT3) acts as an angiogenic signalling nexus that is absolutely necessary to 
orchestrate the angiogenic response through hypoxia inducible factor (HIF) and VEGF-A [49]. Within 
multiple MPNSTs, we identified STAT3 as a common point of convergence for many RTKs involved in 
the angiogenic response, where STAT3 inhibition by drug and/or knockdown was sufficient to 
prevent cell migration/invasion and tumour formation [49]. Of particular interest, STAT3 inhibition 
through knockdown completely ablated expression of HIF-ϭα, HIF-Ϯα aŶd VEGF-A. This work reveals 
that therapeutic strategies that taƌget the STATϯ/HIFϭα pathǁay oƌ pathǁays that ĐoŶǀeƌge oŶ 
STAT3 might be a viable treatment option for NF1 patients. It is also possible that acquired drug 
resistance after STAT3 drug inhibition would be less of a concern, when compared to current TKI 
therapies that target VEGFR. For instance, while Sorafenib prolongs progression-free survival for 
advanced renal cell carcinoma, ranging from 3-6 months, some tumours show primary resistance 
and others acquire resistance to treatment over time. This drug resistance is likely due to activation 
of compensatory signalling pathways that coordinate tumour revascularisation, where a multitude of 
pro-angiogenic factors (such as VEGF, FGFs, EGF, and IL-8 (as well as others)) signal through a 
network of target RTKs to elicit the pro-angiogenic response. Consequently, angiogenic signalling is 
highly flexible, driven through multiple RTKs and where signalling cross-talk between receptors is 
also evident. This level of flexibility hampers current TKI therapies. As STAT3 is a common 
downstream target that is shared by many RTKs, targeting the STAT3 pathway could be a more 
effective anti-angiogenic therapy. 
4.4 Wnt signalling and cancer progression towards MPNSTs 
Comparative transcriptome analysis between neurofibromas and MPNST revealed that the β-
catenin/Wnt signalling was involved in the promotion of MPNST growth [50]. By using an advanced 
DNA transposon-based somatic insertion mutagenesis system, termed sleeping beauty, Watson et 
al. implicated that the Wnt pathway was a malignant driver of neurofibromas [51]. Sleeping beauty 
is a clever forward genetic screen that is capable of identifying both oncogenes and tumour 
suppressors involved in malignant transformation, where insertion of the DNA transposon can either 
drive expression of in-frame genomic sequences (such as oncogenes) or disrupt gene expression 
(such as tumour suppressors). Further confirming WŶt͛s involvement, an independent study 
uncovered 20 genes involved in Wnt signalling that exhibited altered expression in MPNST biopsies 
and cell lines when compared to benign neurofibromas [52]. More recently, pathway analysis 
revealed that the canonical Wnt signalling pathway likely drives MPNST development [46]. In the 
context of cancer, Wnt signalling is typically activated as a consequence of either (i) over-expression 
of Wnt ligand genes, (ii) ŵutatioŶ iŶ the β-catenin gene that causes its activation, or (iii) inactivating 
mutations within genes involved in the proteolytic destƌuĐtioŶ of β-catenin (such as AXIN1, glycogen 
synthase kinase 3 beta (GSK3βͿ, and APC) [53]. Signalling pathways that influence β-catenin 
stabilization can further promote Wnt signalling. For instance, Akt can promote phosphorylation and 
inactivation of GSK3B, ǁhiĐh Đauses staďilizatioŶ of β-catenin [54]. It is important to note that loss of 
PTEN and hyperactivation of PI3K/Akt signalling commonly occurs in human MPNSTs [55]. 
Osteopontin (OPN) is a downstream transcriptional target of Wnt and is highly expressed in 
MPNSTs [46]. In fact, after examining copy number alterations and gene expression, OPN was 
observed to be the most significantly elevated differential expressed gene observed between benign 
and malignant tumours. OPN is a secreted into the extracellular matrix and is a small acidic 
phosphorylated protein that interacts with integrins. OPN is thought to be necessary for the local 
invasive behaviour of cancer cells that is modulated through cell attachment and signalling through 
integrin association, which then facilitates tumour seeding through neovascularisation. In colon 
cancer, where Wnt signalling is a known driver of cancer progression, high expression of OPN was 
found to correlate with poor patient prognosis [56]. While Wnt targets such as OPN could be viable 
biomarkers for MPNSTs, they also have potential for therapy [46]. 
4.5 SUZ12 is an NF1 modifier gene that drives malignancy 
Research into dysregulated pathways within MPNSTs has led to some major advances regarding 
mechanisms of malignancy. One such breakthrough was the discovery that components of the 
chromatin-modifying polycomb repressive complex 2 (PRC2), SUZ12 and EED are frequently 
inactivated through mutations within MPNSTs [57]. De Raedt et al. uncovered that PRC2 functions as 
a tumour suppressor, that when lost, causes marked epigenetic reprogramming that can lead to 
malignancy of plexiform neurofibromas. PRC2 is known to be dysregulated in several human 
tumours, including colon, ovarian, breast and liver [58,59]. SUZ12 lies proximal to the NF1 gene, and 
is considered to cooperate with NF1 to suppress tumour growth. Indeed, more seriously affected 
NF1 patients carry a microdeletion of 17q within their germline that contains NF1, SUZ12 and 12 
neighbouring genes [60]. Such individuals with NF1 microdeletions have a higher prevalence of 
benign tumours and malignancies. Highlighting this cooperative tumour suppressor function 
between both NF1 and SUZ12, knockdown of SUZ12 led to enhanced tumour colony growth in NF1-
deficient malignant glioma cells but not glioblastomas with wild-type NF1 [61]. Furthermore, Nf1+/-; 
Suz12+/- mice had higher tumour burden. Loss of Suz12 is known to modify gene-expression through 
reducing trimethylation of Histone 3 K27 (H3K27me3) and increasing its acetylation (H3K27Ac), 
which results in recruitment of bromodomain proteins and associated transcription factors. By 
blocking this transcriptional switch with a bromodomain inhibitor, JQ1, De Raedt et al. showed that 
they were able to restore the epigenetic status of Suz12-deficient cells to a more normal setting and 
reduced tumour size (up to 68%) in Nf1/TP53/Suz12 heterozygous mice [57]. While this work 
implicates PRC2 as a tumour suppressor in the background of loss of function of NF1, others have 
reported that PRC2 also acts as an oncogene, where SUZ12 is upregulated in several human cancers, 
including lung, colon, ovarian, breast and liver [58,62,63]. De Raedt et al. hypothesised that loss of 
function of both SUZ12 and NF1 synergised to amplify oncogenic RAS signalling to drive malignancy. 
Like TP53, SUZ12 can be considered as a modifier gene in NF1. 
4.6 The role of microRNAs (miRNA) in the formation of MPNSTs 
miRNAs are a type of non-coding RNA, which play a role in regulating functions associated with 
gene expression [64]. Since their discovery approximately 20 years ago, miRNAs have shown to play 
an important role in cancer progression, including involvement in the progression of NF1-associated 
tumours [64,65]. Approximately 50% of miRNA-coding genes have been detected within genomic 
regions of tumour cells [66] and have shown to be involved in tumour metastasis, invasion as well as 
tumour progression. They also contribute to the chemo-resistance and radio-resistance features of 
tumours [64], making them an attractive biomarker and therapeutic targets in cancer. Even though 
the role of miRNAs in NF1 tumour development is still being defined, studies have shown that a 
number of miRNAs could possibly play a role in NF1 tumourgenesis. A microarray analysis based 
study carried out by Presneau et al. revealed that miR-29c was the most significantly downregulated 
miRNA in patient MPNSTs compared to neurofibromas [67]. A list of target genes of miR-29c 
included matrix metalloproteinase (MMP)-2, which is known to be involved in cell migration and 
invasion. To further investigate the role of miR-29c an MPNST cell lines were transfected with miR-
29c which resulted in reduced cell invasion. In an earlier study, Subramanian et al. demonstrated 
that miR-34a was also downregulated in MPNST in comparison to neurofibromas. Of interest, forced 
expression of miR-34a in these MPNST cells resulted in apoptosis [68].  
Moreover, miR-204 was shown to play a role in the growth of MPNSTs [69]. As well as NF1-
associated tumours, it has also been shown that miR-204 acts as a tumour suppressor in breast, 
prostate and kidney cancer [70]. A study analysing differentially expressed genes between plexiform 
neurofibromas and MPNSTs, revelled the upregulation of a group of miRNAs (miR-301a, miR19a and 
miR-106b) in MPNSTs that directly target PTEN [71]. Evidently, miRNAs play an important role in 
tumourgenesis in the context of NF1 and may open up new aspects for future therapies. 
5. Conclusion and future research directions 
Since the discovery of the causative NF1 gene, many fundamental advances have been made 
regarding the tumour suppressor function of neurofibromin. While neurofibromin is classically 
known as a RAS GAP, it is clear that neurofibromin is much more multifunctional. Through 
interfacing with the cytoskeletal architecture and membrane structures, neurofibromin acts as a 
scaffold protein that relays signalling events involved in not only cell growth and proliferation, but 
also cell adhesion and migration. This array of attributes intimately links neurofibromin to normal 
neuronal development, but also makes neurofibromin a prominent tumour suppressor. 
Consequently, loss of NF1 can occur in many sporadic cancers and NF1 patients have an increased 
risk of cancer. MPNSTs have been valuable models to uncover and characterise key signature events 
linked to NF1-driven malignancy. Given the mixed heterogeneity of MPNST cells, therapy has been 
unsuccessful to date. However, recent advances have implicated several crucial signalling pathways 
involved in MPNST malignant growth and have uncovered new potential drug targets. These include 
the use of chromatin re-modellers to restore the epigenetic status of SUZ12-deficiency as well as to 
block angiogenesis and cell migration that are commonly upregulated in MPNSTs, such as the 
STAT3/HIF and RHO/ROCK signalling pathways. 
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Figure Legends 
Figure 1: functional domains involved in tumour suppression of NF1 Functional domains of NF1 
include the GRD, which inhibits RAS GTPases (by converting them to an inactive GDP-bound status). 
Consequently, loss of NF1 function causes constitutive RAS activation towards an array of 
downstream effectors that include RAF, PI3K, RALGDS and PLCε (as well as others). The SEC14-PH 
module interfaces with both the cytoskeleton and membrane structures and is necessary for NF1 to 
function as a RAS-GAP as well as inhibition of LIMK. NF1 is a substrate of PKA, which inhibits NF1 
through phosphorylation of the CTD. At the N-terminus, CSRD is also highly phosphorylated. FAK and 
CRMP-2 interact with the CTD which is required for neuronal development through regulation of cell 
adhesion and the cytoskeleton. 
Figure 2: Cancer progression of MPNSTs A summary of genetic/molecular events of MPNST cancer 
progression from benign neurofibromas. (i) Gene amplification and/or expression of RTKs and 
signalling components involved in cell migration, adhesion and invasion. (ii) Loss of function 
mutations to tumour suppressors such as TP53, PTEN and RB1, as well as SUZ12 (involved in 
epigenetic changes through chromatin remodelling). (iii) Hyperactivation of a subset of transcription 
factors involved in malignancy that include, STAT3/HIF as well as WNT/β-catenin. Furthermore, 
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